Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

615.O2.8 Advances in Treatment of Acute Myeloid Leukemia in Older Patients

Monday, December 8, 2008: 3:30 PM-5:30 PM
3020-3022-3024 - West (Moscone Center)
Moderators:
Mikkael A. Sekeres, MD, MS and Harry Erba
3:30 PM
Core Binding Factor Acute Myeloid Leukemia of the Elderly Treated with Conventional Chemotherapy : A Collaborative Study of the French CBF AML Intergroup

Thomas Prebet, MD1*, Nicolas Boissel, MD, PhD2*, Christian Recher, MD, PhD3*, Xavier Thomas, MD, PhD4, Jacques Delaunay, MD5*, Jean-Yves Cahn, MD, PhD6, Arnaud Pigneux, MD, PhD7*, Bruno Quesnel, MD, PhD8*, Francis Witz, MD9*, Sylvain Thépot10*, Valérie Ugo, MD11*, Christine Terre12*, Emmanuelle Tavernier, MD, PhD13*, Sylvie Castaigne, MD14, Francois Guilhot, MD15, Hervé Dombret16 and Norbert Vey, MD17

1Hematology departmnent, Institut Paoli Calmettes, Marseille, France
2Hematology Department, Hopital Saint Louis, Paris, France
3CHU Toulouse, Toulouse, France
4Hematology Department, Hopital Edouard Herriot, Lyon, France
5Hematology Department, CHU de Nantes, Nantes, France
6Hematology Department, CHU de Grenoble, Grenoble, France
7CHU Bordeaux, Bordeaux, France
8Hematology Department, CHU Lille, Lille, France
9CHU Nancy, Nancy, France
10Groupe Francophone des Myelodysplasies (GFM), Bobigny, France
11Hematology Department, Centre Hospitalier de Brest, Brest, France
12CH de Versailles
13Hematology department, CHU de Saint Etienne, Saint Etienne, France
14Dept. Hematologie, Hopital Mignot, Le Chesnay, France
15Hopital Jean Bernard, Poitiers, France
16Hopital Saint Louis AP-HP, Paris, France
17Dept. of Hematology, Institut Paoli Clamettes, Marseille, France

3:45 PM
The Impact of FLT3-ITD and NPM1 Mutational Status on the Outcome of ATRA Therapy in Patients with Non-APL AML: Results of the UK MRC AML12 Trial

Rosemary Gale, PhD1, Robert Hills, MA, MSc, DPhil2, Claire Green1*, Yashma Patel1*, Amanda Gilkes2*, Michelle Lazenby2*, Keith Wheatley, DPhil3, David C. Linch, FRCP4 and Alan Burnett2*

1Haematology, 3rd floor, Cancer Institute, Paul O'Gorman Building, London, United Kingdom
2Haematology, School of Medicine, Cardiff University, Cardiff, United Kingdom
3Division of Medical Sciences, Robert Aitken Institute, Birmingham, ARRAY(0xc0fada0)
4Department of Hematology, University College London, London, ARRAY(0xc117b58)

4:00 PM
Older Age Is An Independent Risk Factor in AML

Thomas Buchner1, Wolfgang E. Berdel2, Claudia Haferlach3*, Susanne Schnittger3*, Torsten Haferlach, MD3, Hubert Serve4*, Carsten Müller-Tidow1*, Jan Braess5*, Karsten Spiekermann5*, Joachim Kienast1*, Rolf Mesters1, Sarah Volpert6*, Peter Staib7*, Andreas Grüneisen8*, Wolfgang Kern3*, Albrecht Reichle9*, Wolf-Dieter Ludwig10, Georg Maschmeyer11*, Ludwig Balleisen12*, Hartmut Eimermacher13*, Carlo Aul14*, Aristoteles Giagounidis14*, Herbert Rasche15*, Ruediger Hehlmann16, Eva Lengfelder16*, Wolfgang Koepcke17*, Utz O. Krug1*, Maria Cristina Sauerland17*, Achim Heinecke17*, Bernhard Josef Woermann18 and Wolfgang Hiddemann, MD19

1Dept. of Internal Medicine, Hematology/Oncology, University of Münster, Münster, Germany
2Department of Medicine, Hematology and Oncology, University of Münster, Münster, Germany
3MLL Munich Leukemia Laboratory GmbH, Munich, Germany
4Dept. of Internal Medicine, University Hospital of Frankfurt, Frankfurt, Germany
5III. Dept. of Internal Medicine, University of Munich, Munich, Germany
6Dept. of Human Genetics, University of Münster, Münster, Germany
7Dept. of Hematology/ Oncology, St. Antonius Hospital, Eschweiler, Germany
8Dept. of Hematology/Oncology, Vivantes Clinic Neukölln, Berlin
9Dept. of Hematology/Oncology, University of Regensburg, Regensburg, Germany
10Dept. of Hematology/ Oncology, Robert-Roessle-Clinic, Charite, Berlin, Germany
11Dept. of Hematology/Oncology, Ernst-von-Bergmann Clinic, Potsdam, Germany
12Dept. of Hematology/Oncology, Evangel. Hospital Hamm, Hamm, Germany
13Dept. of Hematology/ Oncology, KKH St. Marien Hospital, Hagen, Germany
14Medical Clinic II, St. Johannes Hospital, Duisburg, Germany
15Dept. of Hematology/Oncology, Klinikum Bremen-Mitte, Bremen, Germany
16Dept. of Hematology/Oncology, University of Heidelberg, Mannheim, Germany
17Dept. of Medical Informatics and Biomathematics, University of Münster, Münster, Germany
18Stadtische Kliniken Braunschweig, Braunschweig, Germany
19Department of Internal Medicine III, University of Munich-Hopsital Großhadern, Munich, Germany

4:15 PM
Improved Outcome with Androgens as Maintenance Treatment in Elderly Patients with Acute Myeloid Leukemia after ICL Regimen as Induction Therapy: Results of the GOELAMS SA-2002 Multicenter Phase III Randomized Open Trial

Arnaud Pigneux, MD, PhD1*, Chantal Himberlin, MD2*, Mathilde Hunault-Berger, MD, PhD3*, Francis Witz, MD4*, Christian Recher, MD, PhD5*, Jean-Luc Harousseau, MD6*, Olivier Tournilhac, MD, PhD7*, Christian Berthou, MD, PhD8*, Martine Escoffre-Barbe, MD9*, Denis Guyotat, MD, PhD10*, Nathalie Fegueux, MD11*, Martine Delain, MD12*, Bruno Lioure, MD13*, Eric Jourdan, MD, PhD14*, Didier Bouscary, MD, PhD15*, Laurence Legros, MD, PhD16*, Noel Milpied, MD17*, Frederic Bauduer, MD18*, Frederic Perry17*, Isabelle Luquet, MD, PhD19*, Marie-Christine Bene, MD, PhD20*, Norbert Ifrah, MD3, Jean-Jacques Sotto, MD, PhD21* and Philippe Guardiola, MD3

1CHU Bordeaux, Bordeaux, France
2Unité d'hématologie clinique, Hôpital Robert Debré, Reims, France
3Service des Maladies du Sang, CHU Angers, Angers, France
4Hématologie - Médecine interne, Hôpitaux de Brabois, Nancy, France
5Service d'Hématologie, CHU Toulouse, Inserm U563, Toulouse, France
6Département d'Hématologie, Hôpital Hôtel Dieu, Nantes, France
7Hematology, CHU Clermont Ferrand, Clermont Ferrand, France
8Institut d'Hématologie et de Cancérologie, Hôpital Augustin Morvan, Brest, France
9Hématologie clinique, Hôpital Pontchaillou, Rennes, France
10Hématologie, Institut de Cancérologie de la Loire, Saint Etienne, France
11Service Oncologie et Hématologie, Hôpital Lapeyronie, Montpellier, France
12Hématologie, Hôpital Bretonneau, Tours, France
13Département d'Hématologie et d'Oncologie, CHU Hautepierre, Strasbourg, France
14Médecine B – Unité Onco-Hématologie, Hôpital Caremeau, Nimes, France
15Hematologie, Institut Cochin, Paris, France
16Fédération de Médecine Interne-Hématologie, Hôpital Archet 1, Nice, France
17Hématologie, CHU de Bordeaux, Bordeaux, France
18Hematologie, Centre Hospitalier Côte Basque, Bayonne, France
19Laboratoire central d'Hématologie, Hôpital Robert Debré, Reims, France
20Immunologie, Faculté de Médecine, Nancy, France
21Hématologie clinique, Hôpital Michallon, Grenoble, France

4:30 PM
Impact of Post-Remission Treatments in Patients Aged 65-70 Years with De Novo AML: A Comparison of Two Concomitant Randomized ALFA Trials with Overlapping Age Inclusion Criteria

Raphael Itzykson1*, Claude Gardin2*, Cécile Pautas3*, Xavier Thomas4, Pascal Turlure5*, Emmanuel Raffoux1*, Christine Terré6*, Sylvie Castaigne6*, Hervé Dombret1 and Nicolas Boissel1*

1Hôpital Saint-Louis, AP-HP, Paris, France
2Hôpital Avicenne, AP-HP, Bobigny, France
3Hôpital Henri Mondor, AP-HP, Créteil, France
4Hôpital Edouard Herriot, Lyon, France
5CHU, Limoges, France
6Hôpital Mignot, Versailles, France

4:45 PM
Phase II Study of Single Agent Clofarabine in Previously Untreated Older Adult Patients with Acute Myelogenous Leukemia (AML) Unlikely to Benefit from Standard Induction Chemotherapy

Harry Paul Erba, MD, PhD1, Hagop Kantarjian2*, David F. Claxton, MD3*, M. Arellano4*, Roger M Lyons, MD5, Tibor J. Kovacsovics, MD6, Janice Gabrilove, MD7, Stephen Eckert, Ph.D8*, Rekha Abichandani, MD9* and Stefan Faderl, MD2

1Univ. of Michigan Health System, Ann Arbor, MI
2M.D. Anderson Cancer Center, Houston, TX
3Hematology-Oncology, Penn State Milton S. Hershey Medical Center, Hershey, PA
4Emory University, Atlanta, GA
5Cancer Care Centers South Texas/US Oncology, San Antonio, TX
6Ctr. for Hematological Malignancies, OHSU, Portland, OR
7Mount Sinai School of Medicine, New York, NY
8BioMedical Data Sciences & Informatics, Genzyme Corporation, San Antonio, TX
9Clinical Research, Genzyme Corporation, Cambridge, MA

5:00 PM
Role of Etoposide in Combination with All-Trans Retinoic Acid in the Treatment of Elderly Patients with Acute Myeloid Leukemia and NPM1 Mutation

Marie-Luise Hütter1*, Konstanze Döhner1*, Ingo G.H. Schmidt-Wolf2*, Francisco del Valle3*, Björn Heydrich4*, Wolfgang Heit5*, Walter Fiedler6, Michael Pfreundschuh, MD, PhD7, Gudrun Russ8*, Martin Bentz9*, Aruna Raghavachar10*, Detlef Haase, Md, PhD11*, Wolfram Brugger, MD12, Katharina Götze13*, Silja Groner1*, Hartmut Döhner1* and Richard Schlenk1

1Internal Medicine III, University of Ulm, Ulm, Germany
2CIO, Med. Klinik und Poliklinik III, University of Bonn, Bonn, Germany
3Klinik für Onkologie und Hämatologie, Klinikum Oldenburg gGmbH, Oldenburg, Germany
4II. Medizinische Klinik u. Poliklinik, Universitätsklinikum Kiel, Kiel, Germany
5Hämatologie/Onkologie, Kliniken Essen Süd,, Essen, Germany
6Department of Hematology and Oncology, University Hospital Eppendorf, Hamburg, Germany
7Klinik f. Innere Medizin I, Homburg, Saar, Germany
8Salzburger Landeskliniken, Salzburg, Austria
9Medizinische Klinik II - Hämatologie/Onkologie/Infektionskrankheiten, Städt. Klinikum Karlsruhe gGmbH, Karlsruhe, Germany
10Medizinische Klinik I, Schwerpunkt Hämatologie/Onkologie, HELIOS Klinikum Wuppertal, Wuppertal, Germany
11Hematology and Oncology, University of Göttingen, Göttingen, Germany
12Hematology/Oncology, Schwarzwald-Baar Clinic, Villingen, Germany
13III Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, München, Germany

5:15 PM
Preliminary Results of a Multicenter Phase II Trial of 5-Day Decitabine as Front-Line Therapy for Elderly Patients with Acute Myeloid Leukemia (AML)Clinically Relevant Abstract

Amanda F Cashen, MD1, Gary J. Schiller, MD, FACP2, Margaret R. O'Donnell, MD3*, Julie S. Larsen, PharmD4*, Akhil Baranwal, MD4*, Michael T Cullen, MD4* and John F DiPersio, MD, PhD1

1Washington University School of Medicine, Saint Louis, MO
2UCLA School of Medicine, Los Angeles, CA
3City of Hope Nat'l. Medical Ctr., Duarte, CA
4Clinical Research, Eisai, Inc., Woodcliff Lakes, NJ

*signifies non-member of ASH